SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc., (OTCBB:AEMD) announced today that researchers have discovered the Aethlon Hemopurifier® is effective in capturing particles that suppress the immune response in cancer patients. The particles, known as exosomes, are released by solid tumors, lymphomas, and leukemia. Exosomes induce T-cell apoptosis (programmed cell death), and block T-cell signaling, proliferation, and cytokine production. High concentrations of circulating exosomes correlate with reduced T-cell production and tumor progression in cancer patients.
